Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis.

Tytuł:
The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis.
Autorzy:
Akiyama S; Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois.
Yamada A; Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois; Section of Gastroenterology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan.
Micic D; Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois.
Sakuraba A; Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois. Electronic address: .
Źródło:
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2021 Mar; Vol. 84 (3), pp. 676-690. Date of Electronic Publication: 2020 Aug 11.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
Język:
English
Imprint Name(s):
Original Publication: St. Louis, Mo., Mosby
MeSH Terms:
Antibodies, Monoclonal/*adverse effects
Autoimmune Diseases/*drug therapy
Interleukin-12/*antagonists & inhibitors
Interleukin-23/*antagonists & inhibitors
Lung Diseases, Interstitial/*epidemiology
Respiratory Tract Infections/*epidemiology
Autoimmune Diseases/immunology ; Humans ; Interleukin-12/immunology ; Interleukin-23/immunology ; Lung Diseases, Interstitial/chemically induced ; Lung Diseases, Interstitial/immunology ; Randomized Controlled Trials as Topic ; Respiratory Tract Infections/chemically induced ; Respiratory Tract Infections/immunology ; Respiratory Tract Infections/microbiology
Contributed Indexing:
Keywords: IL12/23 and IL23 antagonists; autoimmune diseases; meta-analysis; noninfectious interstitial lung disease; respiratory tract infections
Substance Nomenclature:
0 (Antibodies, Monoclonal)
0 (Interleukin-23)
187348-17-0 (Interleukin-12)
Entry Date(s):
Date Created: 20200814 Date Completed: 20210728 Latest Revision: 20210728
Update Code:
20240105
PubMed Central ID:
PMC7417275
DOI:
10.1016/j.jaad.2020.08.026
PMID:
32791083
Czasopismo naukowe
Background: Respiratory tract infections (RTIs) and interstitial lung disease (ILD) secondary to interleukin (IL) 12/23 or IL-23 antagonists have been reported in autoimmune diseases.
Objective: To assess the risk of RTIs and noninfectious ILD with these drugs.
Methods: We conducted a systematic review and meta-analysis of randomized controlled trials. Risk of RTIs and noninfectious ILD was compared to placebo by Mantel-Haenszel risk difference. We divided RTIs into upper RTIs (URTI), viral URTIs, and lower RTIs (LRTIs) including infectious pneumonia. Noninfectious ILD included ILD, eosinophilic pneumonia, and pneumonitis.
Results: We identified 54 randomized controlled trials including 10,907 patients with 6 IL-12/23 or IL-23 antagonists and 5175 patients with placebo. These drugs significantly increased the risk of RTIs (Mantel-Haenszel risk difference, 0.019; 95% confidence interval, 0.005-0.033; P = .007), which was attributed to URTIs, but not viral URTIs or LRTIs. There was no significant difference in infectious pneumonia and noninfectious ILD between 2 groups.
Limitations: Because of the rarity of infectious pneumonia and ILD, sensitivity analysis was required.
Conclusions: The use of IL-12/23 or IL-23 antagonists for autoimmune diseases increased the risk of URTIs, but not viral URTIs, LRTIs, and noninfectious ILD.
(Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
Comment in: J Am Acad Dermatol. 2021 Mar;84(3):e161-e162. (PMID: 33039482)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies